Understanding potential non-malarial benefits of sulfadoxine-pyrimethamine treatment during pregnancy on birthweight: a scoping review
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background:
Malaria in pregnancy affects both maternal and infant health. The World Health Organization recommends administering at least three doses of intermittent preventive treatment (IPTp) using sulfadoxine-pyrimethamine (SP) in P. falciparum malaria endemic areas during the 2 nd and 3 rd trimester of pregnancy. Recent clinical trials have described antimalarials with superior antimalarial effects in the mother compared to SP but led to inferior impacts on infant health outcomes such as low birthweight. Secondary non-malarial effects of SP are postulated to contribute to foetal growth and infant health; however, these remain poorly defined. In this scoping review, we aimed to improve the current understanding of the overall prophylactic effects of antimalarial drug use in pregnant women.
Methods:
A systematic search using PubMed, Embase and CENTRAL databases in May 2024 was conducted in accordance with PRISMA-ScR guidelines. Results from randomized controlled trials, as well as observational studies, pre-clinical studies, and meta-analysis published between 2004 to 2024 were extracted. Search terms included “malaria” and “pregnancy” and “inflammation” or “angiogenesis” and “birth” in titles or abstracts. The search strategy was expanded to exclude “malaria”, and to include “birthweight” or “birth outcome”. Studies were included if inflammatory and/or placental angiogenesis biomarkers and birthweights were reported.
Results
Following a blind review of 111 articles by two reviewers, 12 were included to chart key results. Three additional studies were included by citation and website search. The results indicated that the potential non-malarial benefit of SP may primarily include: i) reduction of systemic or off-target local inflammation or ii) positive regulation of placental angiogenesis or both. Data gaps were identified and addressed as several action measures proposed for consideration in future studies.
Conclusion:
Characterization of potential off-target effects of IPTp-SP on improving birthweight could include biomarker data for inflammation, and placental angiogenesis, categorized by gravidity and at multiple time points throughout the chemoprevention period. Inclusion of such data in future empirical studies is anticipated to facilitate our understanding and estimation of the overall public health impact of current IPTp drugs. This could aid clarification of concepts of secondary benefits to support informing preferred product characteristics for IPTp candidates.
